202 related articles for article (PubMed ID: 29468927)
1. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.
Amatore F; Gorvel L; Olive D
Expert Opin Ther Targets; 2018 Apr; 22(4):343-351. PubMed ID: 29468927
[TBL] [Abstract][Full Text] [Related]
2. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
Amatore F; Gorvel L; Olive D
Expert Opin Biol Ther; 2020 Feb; 20(2):141-150. PubMed ID: 31738626
[No Abstract] [Full Text] [Related]
3. Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.
Le KS; Thibult ML; Just-Landi S; Pastor S; Gondois-Rey F; Granjeaud S; Broussais F; Bouabdallah R; Colisson R; Caux C; Ménétrier-Caux C; Leroux D; Xerri L; Olive D
Cancer Res; 2016 Aug; 76(16):4648-60. PubMed ID: 27246829
[TBL] [Abstract][Full Text] [Related]
4. ICOS
Li DY; Xiong XZ
Front Immunol; 2020; 11():2104. PubMed ID: 32983168
[TBL] [Abstract][Full Text] [Related]
5. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
6. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Hanson A; Elpek K; Duong E; Shallberg L; Fan M; Johnson C; Wallace M; Mabry GR; Sazinsky S; Pepper L; Shu CJ; Sathyanarayanan S; Zuerndorfer S; Simpson T; Gostissa M; Briskin M; Law D; Michaelson J; Harvey CJ
PLoS One; 2020; 15(9):e0239595. PubMed ID: 32970735
[TBL] [Abstract][Full Text] [Related]
7. ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy.
Marinelli O; Nabissi M; Morelli MB; Torquati L; Amantini C; Santoni G
Curr Protein Pept Sci; 2018; 19(11):1107-1113. PubMed ID: 29879883
[TBL] [Abstract][Full Text] [Related]
8. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction.
Abdel-Rahman SA; Santini BL; Calvo-Barreiro L; Zacharias M; Gabr M
Bioorg Med Chem Lett; 2024 Feb; 99():129599. PubMed ID: 38185345
[TBL] [Abstract][Full Text] [Related]
9. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
[TBL] [Abstract][Full Text] [Related]
10. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
Sainson RCA; Thotakura AK; Kosmac M; Borhis G; Parveen N; Kimber R; Carvalho J; Henderson SJ; Pryke KL; Okell T; O'Leary S; Ball S; Van Krinks C; Gamand L; Taggart E; Pring EJ; Ali H; Craig H; Wong VWY; Liang Q; Rowlands RJ; Lecointre M; Campbell J; Kirby I; Melvin D; Germaschewski V; Oelmann E; Quaratino S; McCourt M
Cancer Immunol Res; 2020 Dec; 8(12):1568-1582. PubMed ID: 32999002
[TBL] [Abstract][Full Text] [Related]
11. ICOS mediates the generation and function of CD4+CD25+Foxp3+ regulatory T cells conveying respiratory tolerance.
Busse M; Krech M; Meyer-Bahlburg A; Hennig C; Hansen G
J Immunol; 2012 Aug; 189(4):1975-82. PubMed ID: 22815292
[TBL] [Abstract][Full Text] [Related]
12. Agonizing over the Stimulatory Immune Checkpoint ICOS.
Lee JC; Fong L
Clin Cancer Res; 2022 Sep; 28(17):3633-3635. PubMed ID: 35792807
[TBL] [Abstract][Full Text] [Related]
13. Immuno-PET Monitoring of CD8
Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Zamarin D; Holmgaard RB; Ricca J; Plitt T; Palese P; Sharma P; Merghoub T; Wolchok JD; Allison JP
Nat Commun; 2017 Feb; 8():14340. PubMed ID: 28194010
[TBL] [Abstract][Full Text] [Related]
15. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
17. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Yap TA; Gainor JF; Callahan MK; Falchook GS; Pachynski RK; LoRusso P; Kummar S; Gibney GT; Burris HA; Tykodi SS; Rahma OE; Seiwert TY; Papadopoulos KP; Blum Murphy M; Park H; Hanson A; Hashambhoy-Ramsay Y; McGrath L; Hooper E; Xiao X; Cohen H; Fan M; Felitsky D; Hart C; McComb R; Brown K; Sepahi A; Jimenez J; Zhang W; Baeck J; Laken H; Murray R; Trehu E; Harvey CJ
Clin Cancer Res; 2022 Sep; 28(17):3695-3708. PubMed ID: 35511938
[TBL] [Abstract][Full Text] [Related]
19. IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age.
Raynor J; Karns R; Almanan M; Li KP; Divanovic S; Chougnet CA; Hildeman DA
J Immunol; 2015 Aug; 195(3):944-52. PubMed ID: 26109645
[TBL] [Abstract][Full Text] [Related]
20. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
